INTRODUCTION
Botulinum neurotoxins (BoNTs) modulate cholinergic nerve terminals to cause a severe fatal illness, botulism. They are the most potent known protein toxins. There are seven serotypically distinct forms of BoNT, labelled A-G, expressed by various Clostridium strains. They are composed of a 150 kDa di-chain molecule that follows the AB bacterial toxin motif with intracellular targets. Upon binding and internalisation in neuronal cells the toxin blocks neurotransmitter release, leading to flaccid paralysis and potentially death. Despite their high toxicity, various preparations of BoNTs are available commercially for the treatment of muscular overactivity where at safe doses they can be used as therapeutic and cosmetic agents (Barnes et al., 2007; Moore et al., 2007) .
BoNTs are synthesised as single polypeptides cleaved by clostridial or host proteases to its active form. The C-terminal heavy chain composes the binding (Hc) and translocation (Hn) domains of 50 kDa each, and is linked by a single disulfide bridge to the catalytic light chain (LC), a zinc endopeptidase. A loop from Hn wraps around the LC. The loop is called the belt region and is common to all BoNTs for which structural information is available. It is believed to play an essential chaperone role in the molecules' toxicity Galloux et al., 2008) . BoNTs bind specifically to the nerve terminals and are endocytosed into a vesicle where the acidic environment provokes conformational changes. This allows the Hn domain to mediate translocation of LC via pore formation across the endosomal membrane into the cytosol (Koriazova and Montal, 2003; . The protease domain is then free to cleave one of the soluble N-ethyl-maleimidesensitive fusion protein attachment receptor (SNARE) proteins. These proteins form a complex essential in the docking and fusion of synaptic vesicle (Sudhof et al., 2009 ).
Impairing the function of the SNARE complex causes inhibition of neurotransmission and hence paralysis.
The proteolytic activity of each BoNT serotype targets one of the SNARE proteins at a distinct site. BoNT/A and E cleave the pre-synaptic membrane protein SNAP-25 (synaptosomal associated protein of 25 kDa), whereas serotypes B, D, F and G are responsible for the cleavage of the vesicle associated membrane protein (VAMP), also known as synaptobrevin and cellubrevin. Unlike the other serotypes BoNT/C can proteolyse two SNARE proteins, both SNAP-25 and syntaxin. Substrate recognition has been a point of attention since it relies on an extended set of exosites located downstream and upstream of the scissile bond (Breidenbach and Brünger, 2004; Chen et al., 2007 Chen et al., , 2008 Sikorra et al., 2008; Agarwal et al., 2009) . Crystallographic evidence of SNAP-25 bound to LC/A highlighted this complex interaction with the substrate wrapping around LC (Breidenbach and Brünger, 2004) . More recently, several mutation and kinetic studies with VAMP-2 illustrated the important regions for proteolysis of the VAMP specific Clostridial toxins (Chen et al., 2008; Sikorra et al., 2008) . Alongside the structure of LC/F in complex with peptide inhibitors (Agarwal et al., 2009 ), this suggests a common mode of an extended substrate binding, each presenting with a different set of enzyme-substrate interactions.
Trypsinization of BoNT/A led to the discovery of an active fragment composed of the LC and Hn domains only, termed LHn/A (Shone et al., 1985) . This fragment was later recombinantly expressed and showed catalytic properties similar to the parent toxin. This fragment was active on cells when added at high concentration (Chaddock et al., 2002) . A more recent study again confirmed the ability of LHn/A to become internalized and act on the intracellular substrate despite lacking the binding domain (Hc) (Fischer et al., 2008) .
Furthermore, the crystal structure of LHn/A demonstrated that the structures of LC and Hn are not destabilized by deletion of the Hc domain. This makes these proteins attractive candidates as scaffolds for the design of novel biological therapeutics (Chaddock and Marks, 2006; Foster, 2009; Masuyer et al., 2009 ).
Crystal structures of the full length BoNT/A (Lacy et al., 1998) , B (Swaminathan and Eswaramoorthy, 2000) , and E (Kumaran et al., 2009 ) have been determined, along with the LC of all serotypes (Agarwal et al., 2004 (Agarwal et al., , 2005 Segelke et al., 2004; Arndt et al., 2005 Arndt et al., , 2006 Jin et al., 2007) . All the holotoxin structures available present single domains with similar folds. Nevertheless, inter-domain contacts were different in the E serotype compared to serotypes A and B. This indicates that BoNTs may be structurally more diverse than expected. A further illustration of this is the belt region from the Hn domain, for which limited information is available. Even though Hn is highly conserved between serotypes, the belt presents the most variation in primary sequence (Lacy and Stevens, 1999) . Indications given from the holotoxin structures have highlighted the essential functional role it may play, and also proved useful in giving clues on substrate binding (Breidenbach and Brünger, 2004) . In this context, LHn fragments represent a useful tool to further investigate the flexibility of the BoNT molecules in giving essential information on the interaction between the functional Hn and LC domains.
Here we report the crystal structure of the LHn fragment from serotype B botulinum neurotoxin at 2.8 Å. It demonstrates the stability of the translocation domain in association with the catalytic light chain. The metalloprotease activity of the parent toxin is conserved and presents differences in VAMP substrate specificity. If applied at suitably high concentrations, this active protease can be translocated inside neuronal cells despite the lack of a specific binding domain. It confirms the relevance of LHn/B as a functional molecule and highlights the use of LHn as a tool for deciphering the mechanism of botulinum neurotoxin's action. (Table 1) . Initial phases were obtained by molecular replacement using PHASER (McCoy et al., 2007) with the coordinates of a model based on the LHn fragment of the BoNT/B structure (PDB code 1EPW, Swaminathan and Eswaramoorthy, 2000) .
MATERIALS AND METHODS

LHn
Crystallographic refinement was carried out using REFMAC5 (version 5.5) (Vagin et al., 2004) . Manual adjustments and model fitting was done using COOT (version 0.6.1) (Emsley and Cowtan, 2004) . Water molecules were added at positions where F o -F c electron density peaks exceeded 3σ and potential H-bonds could be made. The structure was validated using MOLPROBITY (Davis et al., 2007) . Structure figures were drawn with PyMOL (DeLano Scientific LLC).
Enzymatic assay -LHn/B and BoNT/B (Metabiologics, US) were diluted to 0.1 g/ml in buffer containing 50 mM HEPES pH 7.2, 20 M ZnCl 2 , 1 g/l BSA, 10 mM DTT, and incubated at 37°C for 30 minutes. Recombinant VAMP-1 (2-96), -2 (1-94) and -3 (2-77) substrates were expressed with a C-terminal GFP tag and purified. VAMP-GFP substrates were serial diluted and incubated with the test enzyme at 37°C for 1 hour.
Reactions were stopped by adding 2x reducing sample buffer. Samples were then loaded on to a 4-12 % Bis-Tris gel (Invitrogen) along with BSA standards and visualized by staining with Simply Blue Safestain (Invitrogen). Assay results were quantified by densitometry (Syngene Bioimaging).
Embryonic spinal cord neuron (eSCN) assay -Spinal cords dissected from 14-15
day old foetal Sprague Dawley rats were cultured for 21 days using a modification of previously described method (Chaddock et al., 2002) . eSCN were treated with serial dilutions of LHn/B and BoNT/B, and incubated at 37 °C with 10% CO 2 for 24 hours. Cells were lysed by removing all media and adding sample buffer (25% NuPAGE buffer, 10 mM DTT). After 20 minutes, samples were transferred into microcentrifuge tubes and heated at 95°C for 5 minutes. All samples were run on 12 % Bis-Tris gels (Invitrogen) and proteins were transferred onto nitrocellulose membranes (Invitrogen) using standard protocols.
VAMP cleavage was monitored by measuring the disappearance of the specific VAMP immunoreactive bands compared to an internal control protein (GAPDH). Specific binding of VAMP-1, -2 and -3 primary antibodies (Abcam #ab3346, #ab3347 and #ab43080) was visualised using peroxidase-conjugated secondary antibodies and an enhanced chemiluminescent (ECL) detection system (Thermo), analysis was performed by densitometry (Syngene Bioimaging).
RESULTS AND DISCUSSION
Structure of LHn/B -The crystal structure of LHn/B has been determined at 2.8 Å resolution. The structure was refined to a final R free = 28.2%, and R cryst = 24.1% (Table 1 , Fig. 1a) , with 97.8% of amino acids in the Ramachandran plot allowed region.
The structure presents the two domains interacting tightly in a di-chain complex.
The successful activation of LHn/B by Factor Xa at the engineered site was confirmed by SDS-PAGE analysis and the crystal structure, which shows a clear evidence of the cleavage by a break in electron density between LC and Hn (Suppl. Fig. S1 ). This region is likely to be particularly important for BoNT activity and Hn-mediated delivery of LC in the cytosol. The resulting LC C-terminus and the disulfide bridge (A Cys 437-B Cys 461) between LC and Hn are stabilised through an anti-parallel -sheet arrangement.
The overall structure of LHn/B (Fig. 1a) resembles BoNT/B without the binding domain, and superposition of LHn/B with its parent toxin gives an overall root mean square deviation of 0.95 Å for 837 C  -atoms (Fig. 1b) . The absence of the 50 kDa binding domain in LHn/B did not produce any major conformational change compared with the structure of full length BoNT/B.
LC is a metalloprotease with the catalytic zinc ion coordinated by the conserved tetrahedral arrangement of His 229, His 233, Glu 267 and a water molecule hydrogen bonded to Glu 230. While LC is fairly conserved among BoNTs, its activity is regulated by a complex substrate binding mechanism relying on dispersed exosites, away from the catalytic site, and in the case of BoNT/A the movement of flexible loop regions (Breidenbach and Brünger, 2004) . The unstructured regions seen in LHn/B follow the same arrangements as seen in the full length toxin (Fig. 1) . Residues 208-218, downstream of the active site, could not be modelled due to the lack of electron density. This may be the result of the loop's flexibility, even though the holotoxin structure shows it to be stabilised by interactions with helices 17 and 19 of Hn (Swaminathan and Eswaramoorthy, 2000) .
Three long anti-parallel helices structure the Hn domain. The newly accessible solvent area left open by the lack of binding domain represents 1880 Å 2 and shows weak electrostatic potential (Suppl. Fig. S2 ). The interface between Hn and Hc of the holotoxin is based on 12 potential hydrogen bonds and some weaker van der Waals' contacts between loop 916-920 of Hc and helix 20 of Hn, as well as between the short linker helix of Hc subdomains and loop 610-615 (Hn) (Swaminathan and Eswaramoorthy, 2000) . The loop between residues 626-630 and the last 10 C-terminal residues (including the poly-His tag)
of LHn/B could not be modelled due to lack of electron density. Strong inter-helical interactions allow Hn to keep its long helical conformation as illustrated by the perfect superposition of LHn/B with BoNT/B (Fig. 1b) . The belt of Hn surrounding LC appears to be important for aspects of BoNT activity. The LHn/B structure demonstrates that the stability of this fold is based on strong interactions with LC and is similar to that seen in the holotoxin structure.
The crystallographic studies of LHn, serotypes A and B, highlight the exceptional structural stability of these fragments when compared to their parent holotoxins. LHn/A has been shown to conserve not only the structure, but also the catalytic property of BoNT/A, as well as a potential for intracellular activity (Chaddock et al., 2002; Fischer et al., 2008; Masuyer et al., 2009) . Analysing the functionality of these fragments can therefore help understand the relationship between BoNT domains.
Proteolytic activity of LHn/B -The ability of LHn/B to retain its proteolytic activity was tested by looking at the cleavage of VAMP-1, -2 and -3. The three substrates were recombinantly produced as GFP-tagged constructs and were successfully hydrolysed by LHn/B (Fig. 2a) . The cleavage site was checked for each substrate by N-terminal sequencing (Alta Bioscience, UK) and confirmed to be at the expected position, corresponding to the site of BoNT/B action (Fig. 2a) .
A quantitative analysis of VAMP cleavage was performed by testing a range of different substrate concentrations at a fixed concentration of LHn/B (0.01 g/ml BoNT, with residues within close distance of the scissile bond influencing the catalytic rate of reaction whereas several exosites on both sides of the bond were involved in binding (Chen et al., 2008) . The primary sequences of the three VAMP tested (Fig. 2b) show that the scissile bond area is generally very conserved, apart for a minor difference at position P2 in VAMP-1 (VAMP-1/S -VAMP-2-3/T). This high degree of sequence conservation may explain the low variation in Km observed between the three substrates. The sequence alignment presents only one noticeable difference between VAMP-1 and -2 compared to VAMP-3 that lies near to the previously identified BoNT binding regions (VAMP-1-2/ Ala 39, 37 respectively compared to VAMP-3/ Asn 20). Further work is necessary to determine if this change accounts for the Vmax difference observed for these substrates. Another obvious difference in VAMP-3 compared to VAMP-1 and -2 is the N-terminal region which is considerably shorter and lacking the proline-rich region seen in VAMP-1 and -2.
However, LC/B was proved to efficiently cleave a construct from VAMP-2 lacking residues 1-59 (Chen et al., 2008) . The C-terminal transmembrane regions of the VAMP proteins were not included in these recombinant substrates. These regions were replaced by a GFP-tag and are unlikely to affect substrate binding.
Activity of LHn/B on spinal cord neurons -Studies with BoNT/A have shown that
Hn is necessary for the transport of LC into cells (Koriazova and Montal, 2003 were quantified by densitometry and the proportion of uncleaved VAMP remaining after treatment was plotted (Fig. 3) .
The response followed dose-dependent sigmoidal curves for BoNT/B on VAMP-1 and -2, with sub-picomolar EC50. High concentrations of LHn/B also showed a sigmoidal dose-dependent response with EC50 of 15 and 170 nM on VAMP-2 and -1, respectively.
This suggests that the binding domain of BoNT/B confers the toxin a more than 10 5 -fold better efficiency in reaching its intracellular substrate. This is analogous to the phenomenon seen with BoNT/A and LHn/A where a 10 5 fold difference in concentration was observed on the inhibition of neurosecretion in similar cells (Chaddock et al., 2002) . It is expected that intracellular VAMP cleavage observed here would also result in a similar inhibition of neurotransmission, thus representing a reliable model to assay VAMP-specific BoNTs.
The mechanism of entry of LHn/B into eSCN is unknown but is likely to rely on a non-specific process. Fisher et al. (2008) reported LHn/A's ability to translocate LC over a wide pH range compared to the native toxin, therefore increasing the likelihood of translocation. On the other hand, the possibility of a low affinity receptor for LHn/B in this cell type should not be excluded. The effect observed here is enhanced by the high LHn/B concentration and the sensitivity of the system used for testing. However, further experimental evidence is required to fully understand the mechanism of internalization by the LHn molecule.
BoNT/B and LHn/B both showed higher apparent efficiency in cleaving VAMP-2 compared to VAMP-1 in eSCN (Fig. 3) . However we do not fully understand the significance of this observation. Differences in the immunoreactivity, abundance and subcellular localization of these two SNAREs may play roles in accounting for this observation. VAMP-2 is known to be the most abundant protein in synaptic vesicles (Takamori et al., 2006) . One possibility is that VAMP-2 might compete with VAMP-1 for binding to the LC. We also monitored VAMP-3 in treated eSCN lysates and did not detect any evidence for VAMP-3 cleavage (results not shown). The role of VAMP-3 (also called cellubrevin) has been previously investigated in non-neuronal cells using Clostridial tetanus toxin (McMahon et al., 1996) . This report has highlighted its importance in the recycling of the plasma membrane, early endosome pathways, epithelial cell migration and adhesion (Proux-Gillardeaux et al., 2005) . Despite VAMP-3 homology with VAMP-1 and -2 (Fig.   2b ), there is no strong evidence for a direct role of VAMP-3 in neurosecretion. The lower specificity of LHn/B for this substrate demonstrated in the cell-free assay, along with the lack of intracellular proteolysis in eSCN, suggests that the toxin may have evolved to specifically target SNAREs directly mediating neurotransmission.
CONCLUSION
Botulinum neurotoxins are complex molecules that present a deadly machinery able to specifically inhibit synaptic transmission of cholinergic motorneurons. Each of the toxin's domains is essential for optimal potency and understanding their mechanism will allow to better harness this activity towards novel applications (Foster, 2009) LHn fragments studied so far constitute stable soluble proteins that conserve the functionality of their parent holotoxin but lack the neuron specific targeting conferred by the binding domains of full-length BoNT. These fragments provide additional tools for understanding the structure-function relationship of BoNT domains in the intoxication process, and offer a new strategy for therapeutic and vaccine development (Chaddock and Marks, 2006) . Determining the structure of other LHn serotypes will help refine our knowledge and explain the variations in activities seen between the botulinum neurotoxin serotypes. (B). CLUSTALW alignment (EBI) of human VAMP-1,-2 and -3. Regions important for VAMP-2 cleavage by BoNTs are coloured in grey (Chen et al., 2008; Sikorra et al., 2008) , numbers correspond to VAMP-2 residues. The C-terminal transmembrane domain is indicated. 
